Clinical Trial: A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082868) titled 'A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)' on July 17.

Brief Summary: The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).

Study Start Date: Aug. 18

Study Type: INTERVENTIONAL

Condition: Primary Central Nervous System Lymphoma (PCNSL) Primary Central Nervous System Lymphoma Relapsed Primary Central Nervous System Lymphoma Refractory Primary ...